Dr. Edward Tobinick, founder of the Institute of Neurological Recovery, is the lead author of an observational study in the journal CNS Drugs that provides clinical data supporting the effectiveness of etanercept for improving neurological function following a traumatic brain injury or stroke. The researchers examined 629 individuals treated over a 24 month period. Of the study’s participants, 617 received treatment an average of 42 months after they suffered a stroke and 12 received treatment an average of nearly 10 years following brain injury. The length of time between the event that caused the original injury and the administration of the drug therapy meant the researchers could largely discount spontaneous recovery.
The study focuses on an innovative drug called etanercept, which works by binding to and neutralizing a specific inflammatory molecule called TNF. The drug was delivered to patients using a novel method designed by Dr. Edward Tobinick. The researchers observed many positive effects following the administration of etanercept, including statistically significant improvement in cognition and motor impairment in both the stroke and traumatic brain injury groups.
The findings appear under the title Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury—An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept.